Table 4.
Clinical outcome at 12-month follow-up in the two study subgroups
| Endpoints | Anaemia (N=258) | Non-anaemic (N=603) | p Value |
|---|---|---|---|
| MACCE | 75 (29.1) | 117 (19.4) | 0.002 |
| All-cause mortality | 48 (18.6) | 50 (8.3) | <0.001 |
| Stroke/TIA | 6 (2.3) | 17 (2.8) | 0.819 |
| Peripheral arterial embolism | 2 (0.8) | 5 (0.8) | 1.00 |
| Non-fatal myocardial infarction | 24 (9.3) | 27 (4.5) | 0.011 |
| Any revascularisation | 19 (7.4) | 51 (8.5) | 0.683 |
| Definite/probable stent thrombosis | 10 (3.9) | 4 (0.7) | 0.002 |
| Total bleeding events | 65 (25.2) | 131 (21.7) | 0.059 |
| Minor bleeding (BARC 2) | 22 (8.5) | 48 (8.0) | 0.786 |
| Major bleeding (BARC 3a, 3b, 3c, 5) | 33 (12.8) | 56 (9.3) | 0.142 |
| Access site complications | 25 (9.7) | 49 (8.1) | 0.51 |
| Pseudoaneurysm | 7 (2.7) | 18 (3.0) | 1.0 |
| Red blood cell transfusion | 10 (3.9) | 5 (0.9) | 0.002 |
| Need for corrective surgery | 5 (1.9) | 8 (1.3) | 0.25 |
| Prolonged hospitalisation | 15 (5.8) | 23 (3.8) | 0.21 |
| Total adverse events | 111 (43.0) | 190 (31.5) | 0.001 |
Variables are presented as frequency (percentage).
BARC, Bleeding Academic Research Consortium; MACCE, major adverse cardiac and cerebrovascular events; TIA, transient ischaemic attacks.